Sumitomo Pharma President Kimura (木村) Raises FY2026 Consolidated Earnings Forecast as Key Products Including Gemtesa Outperform Plan in the US

Sumitomo Pharma President Kimura raised the company's consolidated earnings forecast for FY2026. The revision is attributed to key products, including Gemtesa, showing stronger-than-planned growth in the US market.

Read in fullFrom the source, not the headline

sources corroborateOutlets reporting the same event

companies linkedAcross 0 themes, second pass

The story

Sumitomo Pharma raised its consolidated earnings forecast for FY2026. The report cites stronger-than-planned growth in key products in the US market as the reason.

The revision is attributed to key products in the US, including Gemtesa, showing growth above plan. The report does not provide details of President Kimura's comments or specific figures.

At a glance

CompanySumitomo Pharma

RegionsUnited States

ProductGemtesa

NatureFY2026 forecast revised upward

PersonPresident Kimura

DateFY2026

Reference information. Every claim resolves to something the story actually named.

Where this came from

We read each source in full and checked they agree on the core claim.

1/ 1 agree

All of them report the same thing.

www.mixonline.jpNews

AgreesOpen

Read the original articleGo to the source page

Reference information generated from public sources. It does not solicit or advise on investments. Prices are 15-minute delayed.